Research progress on application of nimotuzumab in esophageal cancer
10.3760/cma.j.cn113030-20191023-00429
- VernacularTitle:尼妥珠单抗在食管癌中的应用进展
- Author:
Xiaoqian JIN
1
;
Lan WANG
;
Chun HAN
Author Information
1. 河北医科大学第四医院放疗科，石家庄 050011
- Keywords:
Esophageal neoplasm/targeted therapy;
Nimotuzumab;
Progress
- From:
Chinese Journal of Radiation Oncology
2021;30(7):739-743
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is a common malignant tumor of digestive system in China. Concurrent chemoradiotherapy has become the widely recognized method for the treatment of inoperable locally advanced esophageal carcinoma. Nevertheless, clinical efficacy of concurrent chemoradiotherapy remains to be enhanced. Nimotuzumab, the first human monoclonal antibody to treat malignant tumors in China, has been applied in the treatment of nasopharyngeal carcinoma, glioma, pancreatic cancer and other malignant tumors, which yields significant survival benefits and causes mild adverse events. Hence, more and more scholars are paying attention to its application value in the treatment of esophageal cancer. In this article, research progress on the application of nimotuzumab in esophageal cancer was reviewed, aiming to provide new ideas for the treatment of esophageal cancer.
